Balsm Alofoq Medical Company (TADAWUL:9620)
Saudi Arabia
· Delayed Price · Currency is SAR
77.00
-3.90 (-5.01%)
May 13, 2025, 11:59 AM AST
TADAWUL:9620 Income Statement
Financials in millions SAR. Fiscal year is January - December.
Millions SAR. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Revenue | 18.79 | 18.03 | 17.01 |
| Revenue Growth (YoY) | - | 6.04% | - |
| Cost of Revenue | 9.97 | 9.9 | 8.7 |
| Gross Profit | 8.83 | 8.13 | 8.31 |
| Selling, General & Admin | 5.3 | 4.15 | 4.68 |
| Other Operating Expenses | -0.36 | -0.36 | -0.11 |
| Operating Expenses | 4.78 | 3.79 | 4.58 |
| Operating Income | 4.04 | 4.34 | 3.73 |
| Interest Expense | -0.08 | -0.09 | -0.1 |
| Pretax Income | 3.96 | 4.26 | 3.63 |
| Income Tax Expense | 0.1 | 0.1 | 0.12 |
| Net Income | 3.86 | 4.16 | 3.51 |
| Net Income to Common | 3.86 | 4.16 | 3.51 |
| Net Income Growth | - | 18.47% | - |
| Free Cash Flow | -1.8 | -1.74 | 4.53 |
| Gross Margin | 46.97% | 45.10% | 48.87% |
| Operating Margin | 21.52% | 24.09% | 21.95% |
| Profit Margin | 20.54% | 23.08% | 20.66% |
| Free Cash Flow Margin | -9.59% | -9.65% | 26.61% |
| EBITDA | 4.92 | 5.17 | 4.63 |
| EBITDA Margin | 26.18% | 28.65% | 27.25% |
| D&A For EBITDA | 0.88 | 0.82 | 0.9 |
| EBIT | 4.04 | 4.34 | 3.73 |
| EBIT Margin | 21.52% | 24.09% | 21.95% |
| Effective Tax Rate | 2.54% | 2.27% | 3.32% |
| Advertising Expenses | - | 0.36 | 0.17 |
Source: S&P Global Market Intelligence. Standard template.
Financial Sources.